Chief Justice Susan Christensen has appointed District Court Judge James M. Drew, Hampton, as chief judge of the Second Judicial District. Judge Drew succeeds Chief Judge Kurt Wilke who will retire December 31, 2020. Judge Drew will begin the position of …
Revenue growth reflects rebound of inpatient colonoscopy volumes in Q3 and increased demand for the Pure-Vu system from early adopter hospitals Q3 Pure-Vu-enabled procedures increased by more than 50% above prior quarterly average First major metropolitan …
Early Interim Data for TRIDENT-1 Phase 2 Study of Repotrectinib and Second Drug Candidate, TPX-0022, Recently Presented Phase 2 TRIDENT-1 Registrational Study Full Site Activation and Timeline Update Anticipated in Early 2021 Four Clinical Studies of Three …
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported third …
SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three …
– Strengthened leadership team with appointments of Andrew Hirsch as Chief Executive Officer, William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer – – Completed upsized IPO in October 2020, raising $209.8 million in gross …
BURLINGAME, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the …
NGM continues to demonstrate the productivity of its research discovery engine and progress against its multi-therapeutic area pipeline: -- Initiated a Phase 2 clinical trial of NGM621, an anti-complement C3 antibody, in patients with geographic …
ON 123300, our proprietary multi-kinase inhibitor, enters into the clinic for advanced solid tumors Investigator-initiated study advances with combination of oral rigosertib and nivolumab in K-RAS mutated non-small cell lung cancer Actively evaluating …
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, Chief Scientific Officer, will participate in …
BEIJING, China, Nov. 12, 2020 (GLOBE NEWSWIRE) -- ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG), an international educational services company focused on providing quality learning experiences that cultivate and enhance students’ creativity, …
ATHENS, Greece, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Dynagas LNG Partners LP (NYSE: “DLNG”) (“Dynagas Partners” or the “Partnership”), an owner and operator of liquefied natural gas (“LNG”) carriers, today announced its results for the three and nine months …
DEER PARK, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today reported financial results …
Commercial Launch of Twirla® Expected by Year-End 2020 $71.9 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2020 Management to Host Conference Call today at 4:30 PM ET PRINCETON, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- …
– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies …
- LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease, actively enrolling - Strong cash, cash equivalents and investments balance of $259.9 million as of September 30, …
Third quarter total revenues of $7.4 million rebounding 46% from the second quarter Continued expense reduction actions; third quarter operating costs decreased more than $1 million year-over-year and product sale margins improved by 6% GAAP net loss of $0 …
Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year. Announces Investigational New Drug candidate in oncology, ATYR2810, from its NRP2 antibody …
WEST CHESTER, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, …
COS COB, Conn., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Chicken Soup for the Soul Entertainment Inc. (Nasdaq: CSSE), one of the largest operators of streaming advertising-supported video-on-demand (AVOD) networks, today announced the 30-day extension of a key …
